Relates to access to prescription drugs for chronic weight management
Impact
The bill is expected to have a significant impact on state laws regarding health coverage, particularly by expanding the range of treatments for obesity that must be covered under managed care plans. By doing so, it aligns New York with broader healthcare goals of improving public health and reducing the burden of obesity on the healthcare system. Proponents of the bill argue that this change will lead to better health outcomes for individuals affected by obesity, allowing them to access medications that can support their weight management efforts effectively.
Summary
Bill A10820 proposes an amendment to the social services law to ensure that managed care providers and the medical assistance program are mandated to cover prescription drugs that have been approved by the FDA for chronic weight management in adults who are obese and have at least one weight-related condition. This legislative measure aims to improve access to necessary medications for individuals struggling with obesity, recognizing it as a significant health issue that can lead to various comorbidities.
Contention
However, there may be points of contention surrounding the bill’s implementation. Critics might argue about the potential financial implications for managed care providers and whether this could lead to increased premiums for consumers. Additionally, discussions could arise concerning the definition of 'obesity' and the criteria for coverage, which might affect who qualifies for the benefits under this bill. There could also be debates on the efficacy of weight management drugs and the long-term implications of subsidizing these medications.
Same As
Requires managed care providers and the medical assistance program shall cover prescription drugs approved by the federal food and drug administration for chronic weight management in adults with obesity with at least one weight-related condition.
Relates to including rescue inhaler prescriptions for asthma and other chronic respiratory diseases for individuals under age nineteen in the statewide immunization information system.
Relates to including rescue inhaler prescriptions for asthma and other chronic respiratory diseases for individuals under age nineteen in the statewide immunization information system.
Establishes a pilot program on the referenced rate for prescription drugs; relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.
Relates to the distribution of educational materials regarding the misuse of and addiction to prescription drugs in counties with the most prevalent prescription substance use disorder.
Establishes a pilot program on the referenced rate for prescription drugs; relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.
Relates to the distribution of educational materials regarding the misuse of and addiction to prescription drugs in counties with the most prevalent abuse of prescription opioids.
Authorizes insurance policies which provide coverage for prescription drugs where cost-sharing obligations are determined by category of prescription drugs to offer a program to insureds that utilizes rebates or discounts to lower an insured's cost-sharing for prescription drugs if the insured's cost-sharing under such program would be more favorable than the cost-sharing that would otherwise be applicable to the prescription drug.